Cargando…
Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer
Our retrospective study assessed the efficacy and safety of irinotecan plus raltitrexed in esophageal squamous cell cancer (ESCC) patients who were previously treated with multiple systemic therapies. Between January 2016 and December 2018, records of 38 ESCC patients who underwent irinotecan plus r...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077961/ https://www.ncbi.nlm.nih.gov/pubmed/31917701 http://dx.doi.org/10.1097/CAD.0000000000000891 |
_version_ | 1783507529540567040 |
---|---|
author | Liu, Min Jia, Qingqing Wang, Xiaolin Sun, Changjiang Yang, Jianqi Chen, Yanliang Li, Ying Min, Lingfeng Zhang, Xizhi Zhu, Caiyun Gubat, Johannes Artiaga Chen, Yong |
author_facet | Liu, Min Jia, Qingqing Wang, Xiaolin Sun, Changjiang Yang, Jianqi Chen, Yanliang Li, Ying Min, Lingfeng Zhang, Xizhi Zhu, Caiyun Gubat, Johannes Artiaga Chen, Yong |
author_sort | Liu, Min |
collection | PubMed |
description | Our retrospective study assessed the efficacy and safety of irinotecan plus raltitrexed in esophageal squamous cell cancer (ESCC) patients who were previously treated with multiple systemic therapies. Between January 2016 and December 2018, records of 38 ESCC patients who underwent irinotecan plus raltitrexed chemotherapy after at least one line of chemotherapy were reviewed. Efficacy assessment was performed every two cycles according to the RECIST version 1.1. A total of 95 cycles of chemotherapy were administered, and the median course was 3 (range 2–6). There was no treatment-related death. Nine patients had partial response, 21 had stable disease and eight had progressive disease. The overall objective response rate was 23.68% (9/38) and the disease control rate was78.94% (30/38). After a median follow-up of 18.5 months, the median progression-free survival and overall survival were 105 and 221 days, respectively. There were five patients (13.15%) with grade 3/4 leukopenia, three patients (7.89%) with grade 3/4 neutropenia and one patient (2.63%) with grade 3/4 diarrhea. The combination of irinotecan plus raltitrexed was effective for pretreated ESCC patients. Further studies are needed to determine the optimal dose of the two drugs. |
format | Online Article Text |
id | pubmed-7077961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-70779612020-03-25 Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer Liu, Min Jia, Qingqing Wang, Xiaolin Sun, Changjiang Yang, Jianqi Chen, Yanliang Li, Ying Min, Lingfeng Zhang, Xizhi Zhu, Caiyun Gubat, Johannes Artiaga Chen, Yong Anticancer Drugs Clinical Reports Our retrospective study assessed the efficacy and safety of irinotecan plus raltitrexed in esophageal squamous cell cancer (ESCC) patients who were previously treated with multiple systemic therapies. Between January 2016 and December 2018, records of 38 ESCC patients who underwent irinotecan plus raltitrexed chemotherapy after at least one line of chemotherapy were reviewed. Efficacy assessment was performed every two cycles according to the RECIST version 1.1. A total of 95 cycles of chemotherapy were administered, and the median course was 3 (range 2–6). There was no treatment-related death. Nine patients had partial response, 21 had stable disease and eight had progressive disease. The overall objective response rate was 23.68% (9/38) and the disease control rate was78.94% (30/38). After a median follow-up of 18.5 months, the median progression-free survival and overall survival were 105 and 221 days, respectively. There were five patients (13.15%) with grade 3/4 leukopenia, three patients (7.89%) with grade 3/4 neutropenia and one patient (2.63%) with grade 3/4 diarrhea. The combination of irinotecan plus raltitrexed was effective for pretreated ESCC patients. Further studies are needed to determine the optimal dose of the two drugs. Lippincott Williams & Wilkins 2020-04 2020-03-13 /pmc/articles/PMC7077961/ /pubmed/31917701 http://dx.doi.org/10.1097/CAD.0000000000000891 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/) (CC-BY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Clinical Reports Liu, Min Jia, Qingqing Wang, Xiaolin Sun, Changjiang Yang, Jianqi Chen, Yanliang Li, Ying Min, Lingfeng Zhang, Xizhi Zhu, Caiyun Gubat, Johannes Artiaga Chen, Yong Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer |
title | Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer |
title_full | Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer |
title_fullStr | Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer |
title_full_unstemmed | Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer |
title_short | Clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer |
title_sort | clinical efficacy of irinotecan plus raltitrexed chemotherapy in refractory esophageal squamous cell cancer |
topic | Clinical Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077961/ https://www.ncbi.nlm.nih.gov/pubmed/31917701 http://dx.doi.org/10.1097/CAD.0000000000000891 |
work_keys_str_mv | AT liumin clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer AT jiaqingqing clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer AT wangxiaolin clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer AT sunchangjiang clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer AT yangjianqi clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer AT chenyanliang clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer AT liying clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer AT minlingfeng clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer AT zhangxizhi clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer AT zhucaiyun clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer AT gubatjohannesartiaga clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer AT chenyong clinicalefficacyofirinotecanplusraltitrexedchemotherapyinrefractoryesophagealsquamouscellcancer |